![]() ![]() ![]() There is an insufficient clinical experience to evaluate the risk of hypersensitivity to idarucizumab discontinue if a serious hypersensitivity reaction occurs.Patients treated with dabigatran have underlying disease states that predispose them to thromboembolic events reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease to reduce this risk, resume anticoagulant therapy as soon as medically appropriate.See "What Are Side Effects Associated with Using Idarucizumab?".Do not take Praxbind if you are allergic to idarucizumab or any ingredients contained in this drug. This medication contains idarucizumab.What Are Warnings and Precautions for Idarucizumab? Warnings ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |